CalciMedica to Present at Digestive Disease Week 2024

CalciMedica Inc., a clinical-stage biopharmaceutical enterprise, has received acceptance for an abstract to be presented at the upcoming Digestive Disease Week (DDW) 2024 conference, scheduled from May 18-21 in Washington, DC, with both in-person and virtual attendance options. The abstract, which highlights human proteomics data supporting the positive effects of Auxora™ in severe acute pancreatitis (AP), will be presented by Dr. Richard T. Waldron from Cedars-Sinai Medical Center.

The detailed presentation is set to occur on Saturday, May 18, from 12:30 to 1:30 p.m. ET, under the session titled "Clinical Acute Pancreatitis: Management." The research poster is numbered Sa1468 and will delve into the benefits of the Orai1 inhibitor, Auxora, which has shown promising results similar to those observed in COVID-19 pneumonia cases.

CalciMedica's focus is on developing therapies based on calcium release-activated calcium (CRAC) channel inhibition to address acute and chronic inflammatory and immunologic conditions. The company’s leading product candidate, Auxora™, an intravenous CRAC channel inhibitor, has shown consistently positive outcomes in various clinical trials. Currently, CalciMedica is conducting a Phase 2b trial named CARPO (NCT04681066) targeting AP with systemic inflammatory response syndrome (SIRS), with results expected in the second quarter of 2024. Additionally, a Phase 1/2 study, CRSPA (NCT04195347), is ongoing, and data from this study are anticipated in 2025. Another Phase 2 trial named KOURAGE (NCT06374797) focusing on acute kidney injury (AKI) accompanied by acute hypoxic respiratory failure (AHRF) is set to begin patient enrollment in the second quarter of 2024, with data expected in 2025.

Founded by researchers from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica is headquartered in La Jolla, CA. Their proprietary technology aims to inhibit CRAC channels to better manage the immune response and prevent tissue damage, offering potential treatments for life-threatening inflammatory and immunologic diseases that currently lack approved therapies.

Digestive Disease Week® (DDW) stands as the premier international conference for specialists in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Organized by leading associations including the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW 2024 will feature over 5,600 abstracts and numerous presentations on cutting-edge advancements in gastrointestinal research, medicine, and technology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!